The death rate is about 3% overall, which is the same as

New Post Public Reply Private Reply Replies (0) Message Board
blafarm craigakess #19831
508
Quote:
The death rate is about 3% overall, which is the same as the flu.


You make some very reasonable arguments, and I agree it's smart to try to keep things in perceptive. However, your assertion regarding the fatality rate being equal to the flu is currently impossible to empirically substantiate.

I'm not sure where you are getting your information from, but here are some excerpts from recent stories sourced from legitimate news outlets that may deserve consideration. At the end of the day, we probably won't know the actual fatality rate, and how it compares to the flu, until we get to the end of the first phase of the pandemic (assuming it becomes a full-fledged pandemic).

New York Times:
Link= https://www.nytimes.com/2020/02/29/health/cor...s-flu.html

Quote:
Which virus is deadlier?

The coronavirus seems to be more deadly than the flu — so far.

On average, seasonal flu strains kill about 0.1 percent of people who become infected. The 1918 flu had an unusually high fatality rate, around 2 percent. Because it was so contagious, that flu killed tens of millions of people.

Early estimates of the coronavirus death rate from Wuhan, China, the epicenter of the outbreak, have been around 2 percent. But a new report on 1,099 cases from many parts of China, published on Friday in The New England Journal of Medicine, finds a lower rate: 1.4 percent.

The coronavirus death rate may be even lower, if — as most experts suspect — there are many mild or symptom-free cases that have not been detected.

The true death rate could turn out to be similar to that of a severe seasonal flu, below 1 percent, according to an editorial published in the journal by Dr. Anthony S. Fauci and Dr. H. Clifford Lane, of the National Institute of Allergy and Infectious Diseases, and Dr. Robert R. Redfield, director of the Centers for Disease Control and Prevention.

But even a disease with a relatively low death rate can take a huge toll if enormous numbers of people catch it. As of Sunday, there were about 87,000 coronavirus cases and 3,000 deaths. This week, for the first time, the number of new cases outside China exceeded the number within the country.


U.S. News & World Report:
Link= https://www.usnews.com/news/health-news/artic...y-be-lower

Quote:
The latest tally of almost 1,100 cases of COVID-19 infection from 30 Chinese provinces shows a fatality rate of 1.4% during the early phase of the outbreak.

That's much higher than the rate seen with the seasonal flu, where only about 0.1% of cases end in death. But it's far below the mortality rate of recent coronavirus outbreaks like SARS (9 to 10%) or MERS (36%), noted Dr. Anthony Fauci, director of the U.S. National Institute of Allergy and Infectious Diseases (NIAID).
Furthermore, the 1.4% figure cited in the new Chinese report, published Feb. 28 in the New England Journal of Medicine, is probably higher than the "real" death rate, Fauci added.

That's because many coronavirus cases are so mild they're not even being reported, Fauci explained in an editorial he co-wrote in the same issue of the NEJM. Co-authors include Dr. Robert Redfield, who directs the U.S. Centers for Disease Control and Prevention, and Dr. Clifford Lane, deputy director of the NIAID.
"If one assumes that the number of asymptomatic or minimally symptomatic cases is several times as high as the number of reported cases, the case fatality rate may be considerably less than 1%," Fauci and his colleagues explained.

"This suggests that the overall clinical consequences of COVID-19 may ultimately be more akin to those of a severe seasonal influenza pandemic [which has a case fatality rate of approximately 0.1%] or a pandemic influenza [similar to those in 1957 and 1968]," the experts wrote.


MarketWatch:
Link= https://www.marketwatch.com/story/coronavirus...2020-02-26

Quote:
As the coronavirus spreads, scientists are learning more about the disease’s fatality rate.

The medical journal JAMA released a paper this week analyzing data from the Chinese Center for Disease Control and Prevention on 72,314 coronavirus cases in mainland China, the figure as of Feb. 11, the largest such sample in a study of this kind.

The sample’s overall case-fatality rate was 2.3%, higher than World Health Organization official 0.7% rate. No deaths occurred in those aged 9 years and younger, but cases in those aged 70 to 79 years had an 8% fatality rate and those aged 80 years and older had a fatality rate of 14.8%.

No deaths were reported among mild and severe cases. The fatality rate was 49% among critical cases, and elevated among those with preexisting conditions: 10.5% for people with cardiovascular disease, 7.3% for diabetes, 6.3% for chronic respiratory disease, 6% for hypertension, and 5.6% for cancer.

The fatality rate was 49% among critical cases and worsened among those with preexisting conditions.
The latest China-based study, which was not peer-reviewed by U.S. scientists, found that men had a fatality rate of 2.8% versus 1.7% for women. Some doctors have said that women may have a stronger immune system as a genetic advantage to help babies during pregnancy.

The Chinese study is likely not representative of what might happen if the global spread of the virus worsens, particularly as regards gender. In China, nearly half of men smoke cigarettes versus 2% of women, which could be one reason for the gender disparity.

Coronavirus has an incubation period of up to two weeks, helping the virus to spread. A previous study published in JAMA suggests some patients may be more contagious than others. One patient spread the virus to at least 10 health-care workers and four patients at a hospital in Wuhan.

“In this single-center case series of 138 hospitalized patients with confirmed novel coronavirus–infected pneumonia in Wuhan, China, presumed hospital-related transmission of 2019-nCoV was suspected in 41% of patients, 26% of patients received ICU care, and [the] mortality was 4.3%.”


LiveScience:
Link= https://www.livescience.com/new-coronavirus-c...h-flu.html

Quote:
Death rate

So far this flu season, about 0.05% of people who caught the flu have died from the virus in the U.S., according to CDC data.

The death rate for COVID-19 appears to be higher than that of the flu.

In the study published Feb. 18 in the China CDC Weekly, researchers found a death rate from COVID-19 to be around 2.3% in mainland China. That's much higher than the death rate linked to flu, which is typically around 0.1% in the U.S., according to The New York Times.

Even so, the death rate for COVID-19 varied by location and an individual’s age, among other factors. For instance, in Hubei Province, the epicenter of the outbreak, the death rate reached 2.9%; in other provinces of China, that rate was just 0.4%. In addition, older adults have been hit the hardest. The death rate soars to 14.8% in those 80 and older; among those ages 70 to 79, the COVID-19 death rate in China seems to be about 8%; it’s 3.6% for those ages 60 to 69; 1.3% for 50 to 59; 0.4% for the age group 40 to 49; and just 0.2% for people ages 10 to 39. Nobody 9 and under has died of this coronavirus to date.


The Guardian:
Link= https://www.theguardian.com/world/2020/mar/01...irus-myths

Quote:
Claim: ‘It is no more dangerous than winter flu’

Many individuals who get coronavirus will experience nothing worse than seasonal flu symptoms, but the overall profile of the disease, including its mortality rate, looks more serious. At the start of an outbreak the apparent mortality rate can be an overestimate if a lot of mild cases are being missed. But this week, a WHO expert suggested that this has not been the case with Covid-19. Bruce Aylward, who led an international mission to China to learn about the virus and the country’s response, said the evidence did not suggest that we were only seeing the tip of the iceberg. If borne out by further testing, this could mean that current estimates of a roughly 1% fatality rate are accurate. This would make Covid-19 about 10 times more deadly than seasonal flu, which is estimated to kill between 290,000 and 650,000 people a year globally.


BBC:
Link= https://www.bbc.com/news/health-51674743

_111074816_death_ratio-nc.png

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

JOYEE N01 Debuts Globally with First 2,000 Deliveries

Updated Category News Views 232

JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...

Continue Reading
HONGQI's EHS4 Launch in Europe: Bridging East and West

Updated Category News Views 290

Revving Up a New Chapter: HONGQI in Venice There's a new player in the European automotive scene, and it's rolling in with more style than a Venetian gondola. HONGQI, a name that's been turning gears in China since '58, is packing its suitcases full of Eastern elegance and landing straight in Venice with the all-electric EHS4. On November 16, the brand is set to unveil...

Continue Reading
Shenzhen's Vision Unveiled: APEC 2026 Promo Debut

Updated Category News Views 373

Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...

Continue Reading
Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 104

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading
Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

Updated Category News Views 38

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Continue Reading
EZaccessMD Data Breach: Class Action Lawsuit Looms

Updated Category News Views 675

Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 144

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 136

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
Servier's Data on Tovorafenib Shows Promise in pLGG

Updated Category News Views 607

New Light on a Critical Challenge Talk about a fight in the dark. Pediatric low-grade glioma (pLGG) is a menace that families dread, an uphill battle with odds that feel relentless. Enter Servier and its four-year updated data on OJEMDA® (tovorafenib), a beacon of hope for kids battling these tricky brain tumors. Results, presented at the SNO meeting, are fresh off the...

Continue Reading
Viking Ventures: Impacts of VK2735 on Obesity Examined

Updated Category News Views 21

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

Continue Reading

Top 5 Most Recently Viewed Articles

Major Bitcoin Investor Makes $696 Million Acquisition of BTC

Updated Category News Views 95

Understanding Recent Movements in Bitcoin Investment Bitcoin (BTC) continues to hover between the $62,000 and $63,000 price levels, facing challenges in surpassing the $64,000 mark. Amid this stagnant market behavior, significant interest from large-scale investors, often referred to as 'whales,' is becoming increasingly evident. These bullish activities from crypto...

Continue Reading
Nordic American Tankers Maintains Stability Amid Election Results

Updated Category News Views 133

Nordic American Tankers Shows Confidence Post Election Dear Shareholders and Investors, As we analyze the current business landscape, it is evident that Nordic American Tankers Ltd (NYSE: NAT) is navigating through these times with resilience and assurance. Regardless of the outcome of the presidential election, we foresee minimal immediate effect on our operations or...

Continue Reading
Investors Have a Unique Chance to Lead Fiserv's Securities Case

Updated Category News Views 258

Investors Encouraged to Participate in Fiserv's Legal Battle Faruqi & Faruqi, LLP is reaching out to investors who have experienced financial losses exceeding $75,000 while investing in Fiserv, Inc. This call to action invites affected investors to explore their legal rights in light of recent developments surrounding the company. Understanding the Fiserv Situation The...

Continue Reading
Exploring New Paradigms in U.S. Health and Wellness Trends

Updated Category News Views 217

Innovative Insights into the U.S. Health and Wellness Market A recent national survey, known as the WELLSurvey™, has shed light on the dynamic nature of the U.S. health and wellness market. It reveals the aspirations and attitudes of millions of American households, highlighting a growing trend toward healthier lifestyles. The survey encompasses the perspectives of...

Continue Reading
NW Natural Holdings Declares Increased Quarterly Dividend

Updated Category News Views 134

NW Natural Holdings Declares Increased Quarterly Dividend The Board of Directors of Northwest Natural Holding Company (NYSE: NWN) has officially announced a quarterly dividend of 49 cents per share on the Company's common stock. This decision reflects the company's ongoing commitment to delivering value to its shareholders while maintaining operational excellence....

Continue Reading